Danita Harrison
Nurse Practitioner · Bettendorf, IANPI 1194720649
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,870 of the $6,892 with a category attached, or 70.7%. 26 manufacturers reported payments, led by Medtronic at 46.3% of the total. Reporting peaked in 2022 at $3,416 and has fallen 92.4% since, to $259 in 2025. Among nurse practitioner clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 154 payments — averaging $44.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$3K
- Bayer$585
- Boehringer Ingelheim$495
- Renalytix AI, Inc.$402
- Mannkind Corporation$368
- Sanofi-aventis U.S. LLC$284
- plus $2K from 20 others
What the payments were for
- Travel & lodging$1,68925%
- Food & beverage$4,87071%
- Education$1743%
- Gifts$1192%
- Other$401%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 68 | $3,190 |
| Bayer | 12 | $585 |
| Boehringer Ingelheim | 12 | $495 |
| Renalytix AI, Inc. | 1 | $402 |
| Mannkind Corporation | 8 | $368 |
| Sanofi-aventis U.S. LLC | 3 | $284 |
| Novo Nordisk | 9 | $217 |
| AstraZeneca | 4 | $185 |
| Corcept Therapeutics | 4 | $172 |
| Abbott | 4 | $134 |
| Astellas Pharma US Inc | 1 | $125 |
| Dexcom, Inc. | 3 | $106 |
| Lilly USA, LLC | 5 | $96 |
| AbbVie | 1 | $88 |
| Ablative Solutions, Inc. | 1 | $77 |
| Tandem Diabetes Care, Inc. | 2 | $60 |
| Lexicon Pharmaceuticals, Inc. | 3 | $56 |
| Insulet Corporation | 2 | $54 |
| Novartis | 3 | $50 |
| Xeris Pharmaceuticals, Inc. | 2 | $41 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $26 |
| Exact Sciences | 1 | $19 |
| Averitas Pharma Inc. | 1 | $18 |
| Cvrx, Inc. | 1 | $18 |
| Johnson & Johnson | 1 | $12 |
| Amgen | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 770G$1,509
- Kerendia$456
- KIDNEYINTELX BLOOD COLLECTION CONVENIENCE KIT$402
- MINIMED 780G$229
- JARDIANCE$219
- AFREZZA$134
- TZIELD$129
- AIRSUPRA$127
- Korlym$126
- Veozah$125
How this compares
$6,892 in reported general payments places this provider in the 95th percentile of 1,346 nurse practitioner providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 260 | $325,550 |
| JardianceEmpagliflozin | 302 | $310,751 |
| FarxigaDapagliflozin Propanediol | 164 | $130,212 |
| TrulicityDulaglutide | 78 | $104,624 |
| MounjaroTirzepatide | 64 | $70,855 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 46 | $66,699 |
| Novolog FlexpenInsulin Aspart | 157 | $64,491 |
| Tresiba Flextouch U-100Insulin Degludec | 80 | $63,001 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 69 | $56,203 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 280 | $53,630 |
| Humalog Kwikpen U-100Insulin Lispro | 131 | $48,246 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 27 | $38,340 |
| Humalog Kwikpen U-200Insulin Lispro | 14 | $36,126 |
| RybelsusSemaglutide | 31 | $35,405 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 59 | $33,413 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog, Fiasp, Wegovy | $217 | $432,527415 claims |
| Boehringer IngelheimJardiance | $495 | $310,751302 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog, Insulin Lispro | $96 | $196,647233 claims |
| AstraZenecaFarxiga | $185 | $130,212164 claims |
| BayerKerendia | $585 | $18,77115 claims |
| Sanofi-aventis U.S. LLCLantus | $284 | $1,69914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,346 nurse practitioner providers in Iowa.
Other nurse practitioner in Bettendorf
- Dawnell McIntoshBettendorf$5K
- Nicole MorganDes Moines$106K
- Julie CoffeyIowa City$31K
- Mary JohnsonDavenport$30K
- Megan Hart FernandezCedar Rapids$19K
- Carla HuberCedar Rapids$18K
- Beth ChiaWest Des Moines$15K
- Margaret KinneyRed Oak$13K
- Abbey ModlinDes Moines$12K
- Jonathon HenningsWaterloo$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.